Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07222137 · ClinicalTrials.gov registry record · Phase 3

A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults

A Phase 3 study of Diabetes Mellitus, Type 1, sponsored by Eli Lilly and Company.

Recruiting
Registry status
Phase 3
Development phase
150
Enrollment target
20
Study locations

NCT07222137 is a Phase 3 study of Diabetes Mellitus, Type 1 that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 150 participants, below the 1,265-participant average among 118 other Diabetes Mellitus, Type 1 trials with a reported enrollment target (88% lower). The trial reports 20 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07222137, a Phase 3 study of Diabetes Mellitus, Type 1, is actively recruiting participants, sponsored by Eli Lilly and Company.

RECRUITING
Registry status
Phase 3
Development phase
150 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to find out if baricitinib can delay the onset of clinical type 1 diabetes (T1D) in people who are at high risk to develop T1D. Participation in the study will last up to approximately 5 years.

Conditions Studied

Diabetes Mellitus, Type 1

Interventions

  • DRUG Placebo
  • DRUG Baricitinib

Study Locations (20)

Other

  • Women's and Children's Hospital - Adelaide
  • Box Hill Hospital - Box Hill
  • Royal Brisbane and Women's Hospital - Brisbane
  • Centre for Children's Health Research - Brisbane
  • Royal Children's Hospital - Melbourne
  • The Royal Melbourne Hospital - Parkville
  • Perth Children's Hospital - Perth
  • Sydney Children's Hospital - Randwick
  • The Children's Hospital at Westmead - Westmead
  • UZ Brussel - Brussels
  • Cliniques universitaires Saint-Luc - Brussels
  • Antwerp University Hospital - Edegem
  • UZ Leuven - Leuven

Florida

  • Tallahassee Memorial HealthCare - Tallahassee
  • University of South Florida - Tampa

Iowa

  • University of Iowa - Iowa City
  • Iowa Diabetes and Endocrinology Research Center - West Des Moines

Kentucky

  • Novak Center for Children's Health - Louisville

Pennsylvania

  • Children's Hospital of Philadelphia (CHOP) - Philadelphia

Virginia

  • University of Virginia - Charlottesville

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2026-01-12
Est. Completion 2031-07
Phase Phase 3

Sponsor

Eli Lilly and Company

1,341 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07222137

The ClinicalTrials.gov registry entry for NCT07222137 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,265-participant average among 118 other Diabetes Mellitus, Type 1 trials with a reported enrollment target (88% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Diabetes Mellitus, Type 1 appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT07222137 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Other, Florida, Iowa.

Frequently Asked Questions

What is clinical trial NCT07222137 about?

NCT07222137 is a clinical study titled "A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults". The purpose of this study is to find out if baricitinib can delay the onset of clinical type 1 diabetes (T1D) in people who are at high risk to develop T1D. Participation in the study will last up to approximately 5 years.

What is the current status of trial NCT07222137?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 150 participants. The study started on 2026-01-12. Estimated completion is 2031-07.

What conditions does trial NCT07222137 study?

This clinical trial studies the following conditions: Diabetes Mellitus, Type 1.

What interventions are being tested in trial NCT07222137?

The interventions under investigation include: Placebo (DRUG), Baricitinib (DRUG).

Who is sponsoring clinical trial NCT07222137?

This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07222137 being conducted?

This trial has 20 study locations across Florida, Iowa, Kentucky, Pennsylvania, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Diabetes Mellitus, Type 1

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Diabetes Mellitus, Type 1

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.